A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

PURPOSE: Given that the prognosis of recurrent malignant glioma (MG) remains poor, improving quality of life (QoL) through symptom management is important. Meta-analyses establishing antiemetic guidelines have demonstrated the superiority of palonosetron (PAL) over older 5-hydroxytryptamine 3-recept...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ther Clin Risk Manag
Auteurs principaux: Affronti, Mary Lou, Woodring, Sarah, Peters, Katherine B, Herndon, James E, McSherry, Frances, Healy, Patrick N, Desjardins, Annick, Vredenburgh, James J, Friedman, Henry S
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2016
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5207433/
https://ncbi.nlm.nih.gov/pubmed/28096679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S122480
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires